Enjoy complimentary customisation on priority with our Enterprise License!
The acute myeloid leukemia (AML) treatment market share in APAC is expected to increase by USD 277.03 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.83%.
This acute myeloid leukemia (AML) treatment market in APAC research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers acute myeloid leukemia (AML) treatment market in APAC segmentation by type (chemotherapy, stem cell transplantation, and others) and geography (China, Japan, India, and Rest of APAC). The acute myeloid leukemia (AML) treatment market in APAC report also offers information on several market vendors, including AbbVie Inc., Agios Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. among others.
Download the Free Report Sample to Unlock the Acute Myeloid Leukemia (AML) Treatment Market Size in APAC for the Forecast Period and Other Important Statistics
The high incidence of acute myeloid leukemia is notably driving the acute myeloid leukemia (AML) treatment market growth in APAC, although factors such as lack of adequate healthcare infrastructure in developing nations may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the acute myeloid leukemia (AML) treatment industry in APAC. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Acute Myeloid Leukemia (AML) Treatment Market Driver in APAC
The high incidence of acute myeloid leukemia is one of the key drivers supporting the acute myeloid leukemia (AML) treatment market growth in APAC. For instance, the highest incidence of leukemia was estimated in Australia and New Zealand. The estimated number of new cases in Australia was 4,903 in 2021. Each year, in New Zealand, around 700 adults and 40 children are diagnosed with leukemia. Similarly, according to the Indian Council of Medical Research, the annual incidence of AML is 2-3 per 100,000, more in the age above 65. Moreover, China will witness 14,400 diagnosed incident cases of acute lymphocytic leukemia by 2029. AML treatment in China has been dominated by chemotherapy. Thus, the rising incidence of AML in the region will increase the adoption of treatment during the forecast period.
Key Acute Myeloid Leukemia (AML) Treatment Market Trend in APAC
CAR T-cell therapy for AML is another factor supporting the acute myeloid leukemia (AML) treatment market growth in APAC. It is one of the most promising ways of treating AML, which lets the patient's immune system fight leukemia. T cells are removed from the patient's blood and altered in the lab in this process. These cells are altered with the substance called chimeric antigen receptors (CARs) cells in the lab. It is then grown and infused into the patient's blood, where the leukemia cells act. Early clinical trials have shown some positive results. However, treatment has shown serious side effects in some cases on which doctors are currently working. Clinical approval of such treatment will cure AML very effectively during the forecast period. Such factors are driving the market growth.
Key Acute Myeloid Leukemia (AML) Treatment Market Challenge in APAC
The lack of adequate healthcare infrastructure in developing nations is one of the factors hindering the acute myeloid leukemia (AML) treatment market growth in APAC. Radiotherapy and chemotherapy devices require ample installation space due to their large size. There is a lack of adequate healthcare infrastructure in underdeveloped and emerging economies due to limited healthcare expenditure, which is one of the major factors restraining the adoption of cancer treatment. Only a limited number of healthcare institutions in underdeveloped and developing countries can use advanced radiotherapy systems for cancer treatment. This limits the number of radiotherapy and chemotherapy procedures despite their high demand. Such limitations are expected to impede acute myeloid leukemia (AML) treatment market growth in APAC during the forecast period.
This acute myeloid leukemia (AML) treatment market in APAC analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the acute myeloid leukemia (AML) treatment market growth in APAC as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the acute myeloid leukemia (AML) treatment market in APAC during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the acute myeloid leukemia (AML) treatment market in APAC encompasses successful business strategies deployed by the key vendors. The acute myeloid leukemia (AML) treatment market in APAC is fragmented and the vendors are deploying growth strategies such as focusing on product approvals, M&A, and product launches to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The acute myeloid leukemia (AML) treatment market in APAC forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the acute myeloid leukemia (AML) treatment market in APAC, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market's growth will originate from China during the forecast period. China is the key market for acute myeloid leukemia (AML) treatment market in APAC. Market growth in this region will be slower than the growth of the market in India.
Personalized medicines have high demand in oncology therapy since conventional cancer drug therapies fail to achieve desired patient outcomes. This treatment will facilitate the acute myeloid leukemia (AML) treatment market growth in China over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 pandemic drastically affected China which, in turn, led to radical changes and disturbances in various medical procedures and treatments of AML. However, by January 2021, the number of cases in the country reduced, which led to the resumption of business activities. The resumption of various preclinical studies and pharmaceutical operations will drive the demand for AML treatment in China during the forecast period
To gain further insights on the market contribution of various segments Request for a FREE sample
The acute myeloid leukemia (AML) treatment market share growth in APAC by the chemotherapy segment will be significant during the forecast period. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body, which is very helpful in the treatment of AML as it is the cancer of the blood and bone marrow that spreads in all parts of the body. Therefore, the presence of many chemotherapy drugs for AML in APAC will drive market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the acute myeloid leukemia (AML) treatment market size in APAC and actionable market insights on post COVID-19 impact on each segment.
Acute Myeloid Leukemia (AML) Treatment Market Scope in APAC |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.83% |
Market growth 2022-2026 |
$ 277.03 million |
Market structure |
Fragmented |
YoY growth (%) |
12.56 |
Regional analysis |
APAC |
Performing market contribution |
China at 40% |
Key consumer countries |
China, Japan, and India |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Agios Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.